Western diamondback rattlesnake venom (Crotalus atrox venom)

Crotalus atrox venom is a complex biological mixture secreted by the Western diamondback rattlesnake, consisting of a diverse array of proteins and peptides with potent physiological activities [1]. The primary toxic components include snake venom metalloproteinases (SVMPs), which degrade extracellular matrix proteins leading to hemorrhage and tissue necrosis [1, 2]. Phospholipases A2 (PLA2) are also present, contributing significantly to local inflammation and systemic myotoxicity [1, 2]. Additionally, the venom contains serine proteases that disrupt the coagulation cascade, often resulting in fibrinogenolysis and thrombocytopenia [1, 4]. In medical practice, this venom serves as the target for specific antivenom therapies, such as Crotalidae Polyvalent Immune Fab (CroFab), which employs antibody fragments to neutralize the circulating toxins [3]. These antivenoms work by binding to the venom components, preventing them from interacting with their physiological targets and facilitating their clearance [3]. While primarily known for its role in envenomation, the individual components of Crotalus atrox venom are also valuable tools in biochemical research and drug discovery for conditions like thrombosis and hypertension [2, 4]. Monitoring patients for venom effects involves tracking coagulation parameters and platelet counts to assess the severity of envenomation and the efficacy of treatment [2, 3]. Sources: [1] Calvete JJ, et al. (2009) J Proteome Res. [2] StatPearls (2023) Rattlesnake Envenomation. [3] FDA (2001) CroFab Label. [4] Toxin and Toxin Target Database (T3DB) Crotalus atrox venom.

Other names

Western diamondback rattlesnake venomC. atrox venomWestern diamondback venom

Neutralization of venom components through antibody-mediated binding and clearance [3]